State Key Laboratory of Digestive Disease, Institute of Digestive Disease and The Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China.
Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Gut. 2021 Apr;70(4):761-774. doi: 10.1136/gutjnl-2019-319664. Epub 2020 Jul 21.
Non-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is an increasing healthcare burden worldwide. We examined the role of dietary cholesterol in driving NAFLD-HCC through modulating gut microbiota and its metabolites.
High-fat/high-cholesterol (HFHC), high-fat/low-cholesterol or normal chow diet was fed to C57BL/6 male littermates for 14 months. Cholesterol-lowering drug atorvastatin was administered to HFHC-fed mice. Germ-free mice were transplanted with stools from mice fed different diets to determine the direct role of cholesterol modulated-microbiota in NAFLD-HCC. Gut microbiota was analysed by 16S rRNA sequencing and serum metabolites by liquid chromatography-mass spectrometry (LC-MS) metabolomic analysis. Faecal microbial compositions were examined in 59 hypercholesterolemia patients and 39 healthy controls.
High dietary cholesterol led to the sequential progression of steatosis, steatohepatitis, fibrosis and eventually HCC in mice, concomitant with insulin resistance. Cholesterol-induced NAFLD-HCC formation was associated with gut microbiota dysbiosis. The microbiota composition clustered distinctly along stages of steatosis, steatohepatitis and HCC. and increased sequentially; while and were depleted in HFHC-fed mice, which was corroborated in human hypercholesteremia patients. Dietary cholesterol induced gut bacterial metabolites alteration including increased taurocholic acid and decreased 3-indolepropionic acid. Germ-free mice gavaged with stools from mice fed HFHC manifested hepatic lipid accumulation, inflammation and cell proliferation. Moreover, atorvastatin restored cholesterol-induced gut microbiota dysbiosis and completely prevented NAFLD-HCC development.
Dietary cholesterol drives NAFLD-HCC formation by inducing alteration of gut microbiota and metabolites in mice. Cholesterol inhibitory therapy and gut microbiota manipulation may be effective strategies for NAFLD-HCC prevention.
非酒精性脂肪性肝病(NAFLD)相关肝细胞癌(HCC)是全球日益严重的医疗保健负担。我们研究了膳食胆固醇通过调节肠道微生物群及其代谢物在推动 NAFLD-HCC 中的作用。
14 个月内,给 C57BL/6 雄性同窝仔鼠喂食高脂肪/高胆固醇(HFHC)、高脂肪/低胆固醇或正常饮食。给 HFHC 喂养的小鼠给予降胆固醇药物阿托伐他汀。将来自不同饮食喂养的小鼠的粪便移植到无菌小鼠中,以确定胆固醇调节的微生物群在 NAFLD-HCC 中的直接作用。通过 16S rRNA 测序和液相色谱-质谱(LC-MS)代谢组学分析检测肠道微生物群。检查了 59 名高胆固醇血症患者和 39 名健康对照者的粪便微生物组成。
高膳食胆固醇导致小鼠发生脂肪变性、脂肪性肝炎、纤维化,最终发生 HCC,同时伴有胰岛素抵抗。胆固醇诱导的 NAFLD-HCC 形成与肠道微生物群失调有关。微生物群组成沿着脂肪变性、脂肪性肝炎和 HCC 的阶段明显聚类。和依次增加;而在 HFHC 喂养的小鼠中耗尽,在人类高胆固醇血症患者中也得到证实。膳食胆固醇诱导肠道细菌代谢物改变,包括胆酸增加和 3-吲哚丙酸减少。用 HFHC 喂养的小鼠粪便灌胃的无菌小鼠表现出肝脂质积累、炎症和细胞增殖。此外,阿托伐他汀恢复了胆固醇诱导的肠道微生物群失调,并完全阻止了 NAFLD-HCC 的发生。
膳食胆固醇通过诱导小鼠肠道微生物群和代谢物的改变来驱动 NAFLD-HCC 的形成。胆固醇抑制治疗和肠道微生物群操纵可能是预防 NAFLD-HCC 的有效策略。